Core Viewpoint - Rosen Law Firm is reminding investors who purchased Sarepta Therapeutics, Inc. securities between June 22, 2023, and June 24, 2025, of the upcoming lead plaintiff deadline on August 25, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that Sarepta made false and misleading statements regarding its gene therapy product, ELEVIDYS, which posed significant safety risks and failed to detect severe side effects during trials [5]. - The adverse events related to ELEVIDYS treatment led to a halt in recruitment and dosing in trials, attracting regulatory scrutiny and increasing risks around the therapy's approvals [5].

Company Cracks Top 25 Overall on Forbes' Annual Net Zero LeadersTAMPA, Fla., July 17, 2025 /PRNewswire/ -- Forbes has recognized leading aluminum beverage can manufacturer Crown Holdings, Inc. (NYSE: CCK) (Crown) (www.crowncork.com) as the top packaging company on track to achieve net-zero carbon emissions on its third annual list of Net Zero Leaders. Out of 200 companies evaluated for emissions projections, risk management, financial strength, governance, and organizational preparedness within the context ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - The class action lawsuit has been filed against PepGen Inc. for misleading statements regarding the effectiveness and safety of its drug PGN-EDO51 and the CONNECT2 study [4]. - Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4]. - The deadline to move the Court to serve as lead plaintiff is August 8, 2025 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements about PGN-EDO51's effectiveness and safety, the CONNECT2 study's adequacy for FDA approval, and the overall commercial prospects of the drug [4]. - The misleading public statements led to investor damages when the true information became known [4].

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of 3D Systems Corporation (NYSE: DDD) between August 13, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important August 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased 3D Systems securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of iRobot Corporation securities purchasers during the specified Class Period, indicating potential legal issues for the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between January 29, 2024, and March 11, 2025, and aims to address misleading statements made by iRobot regarding its financial stability and restructuring plans [1][5]. - The lawsuit claims that iRobot overstated the effectiveness of its Restructuring Plan following the termination of the Amazon Acquisition, leading to doubts about its ability to operate profitably as a standalone entity [5]. Group 2: Investor Information - Investors who purchased iRobot securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Apple Inc. for allegedly making false and misleading statements regarding the integration of advanced AI-based features into its devices, which may have impacted investor decisions and the company's financial prospects [4]. Group 1: Class Action Details - The class period for the lawsuit is from June 10, 2024, to June 9, 2025, and the lead plaintiff deadline is August 19, 2025 [1]. - Investors who purchased Apple securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - A lead plaintiff acts on behalf of other class members in directing the litigation and must file a motion with the court by the specified deadline [2]. Group 2: Allegations Against Apple - The lawsuit claims that Apple misstated the timeline for integrating advanced AI-based Siri features, making it unlikely these features would be available for the iPhone 16 [4]. - The absence of these advanced features is alleged to negatively impact iPhone 16 sales, leading to overstated business and financial prospects for Apple [4]. - The lawsuit asserts that Apple's public statements were materially false and misleading throughout the class period, resulting in investor damages when the truth was revealed [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Rocket Pharmaceuticals provided misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) [5]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [5]. - When the true details became public, investors reportedly suffered damages due to the misleading information [5].

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline. SO WHAT: If you purchased DoubleVerify common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of 3D Systems Corporation (NYSE: DDD) between August 13, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important August 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased 3D Systems securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Red Cat Holdings, Inc. securities between March 18, 2022, and January 15, 2025, of the upcoming lead plaintiff deadline on July 22, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Red Cat securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 22, 2025 [2]. - The lawsuit alleges that Red Cat made false and misleading statements regarding its production capacity and the value of its contracts, leading to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements since 2013 [3].